Sight Sciences (NASDAQ:SGHT) Posts Quarterly Earnings Results

Sight Sciences (NASDAQ:SGHT) announced its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.07, FiscalAI reports. The company had revenue of $20.39 million for the quarter, compared to analysts’ expectations of $20.35 million. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.

Here are the key takeaways from Sight Sciences’ conference call:

• 2026 revenue guidance initiated at $82M–$88M (6%–14% growth), with interventional glaucoma $77M–$81M and interventional dry eye $5M–$7M, signaling management’s expectation of a return to growth.
• TearCare reimbursement milestone—TuMax, Novitas and First Coast established pricing for CPT code 0563T and the company sold ~700 Smart Lids to ~80 accounts (≈30 new), validating the reimbursed interventional dry eye commercial model.
• Strong Q4 execution—total revenue $20.4M (+7% YoY), interventional glaucoma $19.7M (+5%), gross margin 87%, and net loss narrowed to $4.2M, reflecting improved profitability and operational discipline.
• OMNI and standalone glaucoma strategy—OMNI grew despite prior LCD headwinds, benefited from higher ASPs (Omni Edge), and the company is investing in pseudophakic market development to expand standalone procedures.
• Cash and expense trade-offs—cash declined to $92M from $120.4M year‑over‑year and management is guiding adjusted operating expenses up to $93M–$96M to fund commercial investments, which could pressure runway if revenue ramp underperforms.

Sight Sciences Price Performance

Shares of NASDAQ SGHT opened at $5.41 on Thursday. The firm has a market cap of $286.03 million, a P/E ratio of -6.01 and a beta of 2.43. The business’s 50 day moving average is $6.39 and its 200-day moving average is $5.76. The company has a current ratio of 9.60, a quick ratio of 8.93 and a debt-to-equity ratio of 0.62. Sight Sciences has a 1-year low of $2.03 and a 1-year high of $9.24.

Insider Transactions at Sight Sciences

In other Sight Sciences news, CFO James Rodberg sold 4,405 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $7.82, for a total transaction of $34,447.10. Following the transaction, the chief financial officer owned 154,440 shares in the company, valued at $1,207,720.80. This trade represents a 2.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jeremy B. Hayden sold 9,385 shares of Sight Sciences stock in a transaction on Monday, January 5th. The stock was sold at an average price of $7.82, for a total value of $73,390.70. Following the sale, the insider directly owned 247,205 shares of the company’s stock, valued at $1,933,143.10. This represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 99,796 shares of company stock valued at $719,722. Corporate insiders own 30.90% of the company’s stock.

Institutional Trading of Sight Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its position in shares of Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after purchasing an additional 3,785 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Sight Sciences by 32.7% in the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after buying an additional 2,875 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Sight Sciences in the second quarter valued at approximately $67,000. O Shaughnessy Asset Management LLC acquired a new stake in Sight Sciences during the fourth quarter worth approximately $81,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Sight Sciences during the fourth quarter worth approximately $96,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Key Headlines Impacting Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Q4 2025 results beat expectations — revenue of $20.4M (up 7% Y/Y) and GAAP loss narrowed to $0.08/sh; operating expenses fell sharply, driving a smaller net loss and showing improved operating discipline. Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
• Positive Sentiment: Management set 2026 revenue guidance of $82M–$88M (growth of ~6%–14%) and expects Interventional Dry Eye to rebound to $5M–$7M (vs $1.6M in 2025), signaling management confidence in commercial recovery and a pathway toward cash‑flow breakeven. Sight Sciences outlines $82M–$88M 2026 revenue target while expanding interventional dry eye strategy
• Positive Sentiment: Gross margins remained very strong (~87% Q4, 86% FY), cash discipline improved (Q4 cash use ~$0.4M) and cash on hand of ~$92M provides runway into 2026 while the company reduces adjusted operating losses. Sight Sciences, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and 2026 Guidance
• Positive Sentiment: At least one sell‑side analyst (Stifel) is bullish on the stock heading into/after earnings, which can support market optimism. Sight Sciences (NASDAQ:SGHT) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says
• Neutral Sentiment: 2026 revenue guidance midpoint (~$85M) is close to but slightly below some consensus estimates (~$86.5M), so guidance is cautiously received — range leaves room for beat/miss vs. street. Sight Sciences Inc (SGHT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic …
• Negative Sentiment: Full‑year 2025 revenue declined ~3% Y/Y and Interventional Dry Eye sales plunged (from ~$4.0M in 2024 to $1.6M in 2025), highlighting execution/market adoption risk in the dry‑eye business despite the 2026 rebound target. Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
• Negative Sentiment: Company expects adjusted operating expenses to rise to $93M–$96M in 2026 (up 6%–9%) to fund market access and commercial expansion, which could pressure near‑term profitability and cash flow if revenue acceleration lags. Sight Sciences outlines $82M–$88M 2026 revenue target while expanding interventional dry eye strategy
• Negative Sentiment: Cash declined Y/Y (from ~$120M to ~$92M) and insider selling activity was notable in recent months — factors worth monitoring for dilution or liquidity risk if execution slows. Sight Sciences, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and 2026 Guidance

Analysts Set New Price Targets

Several analysts have issued reports on SGHT shares. UBS Group upped their price target on shares of Sight Sciences from $7.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research note on Monday, December 29th. Piper Sandler set a $9.00 target price on shares of Sight Sciences in a research note on Monday, January 5th. Raymond James Financial set a $9.00 price target on Sight Sciences in a report on Monday, January 5th. Finally, William Blair upgraded Sight Sciences to a “strong-buy” rating in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sight Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $8.76.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.